PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27888906-6	2016	In contrast, others drugs, such as fibrates and niacin, could decrease PCSK9 levels.	Niacin	48-54	proprotein convertase subtilisin/kexin type 9	Homo sapiens	71-76	
31130489-3	2019	OBJECTIVE: The objective of the study was to determine if addition of PCSK9i to background niacin therapy further lowers Lp(a).	Niacin	91-97	proprotein convertase subtilisin/kexin type 9	Homo sapiens	70-75	
31130489-11	2019	CONCLUSIONS: Our study demonstrates that the addition of PCSK9i to background of niacin therapy is associated with ~15% reduction in Lp(a) beyond that achieved with background niacin monotherapy.	Niacin	81-87	proprotein convertase subtilisin/kexin type 9	Homo sapiens	57-62	
31130489-11	2019	CONCLUSIONS: Our study demonstrates that the addition of PCSK9i to background of niacin therapy is associated with ~15% reduction in Lp(a) beyond that achieved with background niacin monotherapy.	Niacin	176-182	proprotein convertase subtilisin/kexin type 9	Homo sapiens	57-62	
26784936-4	2016	The fatty acid niacin conjugate 5 has been shown to be an inhibitor of the sterol regulatory element binding protein (SREBP), a key regulator of cholesterol metabolism proteins such as PCSK9, HMG-CoA reductase, ATP citrate lyase, and NPC1L1.	Niacin	15-21	proprotein convertase subtilisin/kexin type 9	Homo sapiens	185-190	
26160958-7	2015	Extended-release nicotinic acid also decreased ApoB100 (22%; P=0.008) and proprotein convertase subtilisin/kexin type 9 (PCSK9, -29%; P=0.008) plasma concentrations.	Niacin	17-31	proprotein convertase subtilisin/kexin type 9	Homo sapiens	74-119	
26160958-7	2015	Extended-release nicotinic acid also decreased ApoB100 (22%; P=0.008) and proprotein convertase subtilisin/kexin type 9 (PCSK9, -29%; P=0.008) plasma concentrations.	Niacin	17-31	proprotein convertase subtilisin/kexin type 9	Homo sapiens	121-126	
25432415-2	2015	Although statins and fibrates have been reported to increase plasma PCSK9 levels, the effect of niacin on PCSK9 is unknown.	Niacin	96-102	proprotein convertase subtilisin/kexin type 9	Homo sapiens	106-111	
25432415-7	2015	PCSK9 levels were increased with statin therapy, but decreased with the simvastatin 20 mg/ER niacin combination (mean -13%, CI -3 to -23).	Niacin	93-99	proprotein convertase subtilisin/kexin type 9	Homo sapiens	0-5	
25432415-11	2015	In conclusion, niacin therapy offsets the increase in PCSK9 levels noted with statin and fibrate therapy.	Niacin	15-21	proprotein convertase subtilisin/kexin type 9	Homo sapiens	54-59	
25432415-12	2015	A portion of the low-density lipoprotein cholesterol reduction seen with niacin therapy may be due to reduction in PCSK9.	Niacin	73-79	proprotein convertase subtilisin/kexin type 9	Homo sapiens	115-120